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Proteoglycans (PG) ~  are important tissue components,both in the extracellular 
matrix (1) and as cell membrane-associated components (2). They are composed 
of protein and glycosaminoglycans  (GAG), containing glucosamine or galactosa- 
mine and (generally) uronic acid. About fifty years ago, Goebel (3) demonstrated 
the antigenicity of protein-bound uronic acid and, further, showed that rabbit 
antisera could distinguish protein-bound glucuronic from galacturonic acid (4). 
More recently, the presence  of immunity to  heparan  sulfate and chondroitin 
sulfate PG has been demonstrated in animals (5-7). Both protein core and GAG 
determinants are antigenic. Studies of systemic lupus erythematosus (SLE) sera 
(8) suggest that antibodies to DNA may cross-react with hyaluronate and chon- 
droitin sulfate on a  nonspecific charge basis because of the repeating anionic 
sites that DNA and GAG have in common. 
Previous  studies  (9-13)  suggest that  autoimmunity to  a  number of kidney 
antigens may exist in acute and chronic giomerulonephritis (GN). Our own work 
(13,  14)  suggests that the carbohydrate antigens of the  giomerular basement 
membrane  (GBM)  may  be  antigenic.  Since  one  of the  major  carbohydrate- 
containing antigens of the GBM is heparan sulfate PG (1), we studied the sera of 
patients with acute poststreptococcal glomerulonephritis (PSGN) for the presence 
of antibodies to  glomerular PG.  These  studies demonstrate the  presence,  in 
PSGN  sera,  of antibodies to  glomerular PG.  Heparan  sulfate is  the  primary 
target of immune reactivity. Mammalian hyaluronate and streptococcal hyalu- 
ronate inhibited the observed reactivity, suggesting cross-reactivity in the  im- 
mune response to heparan sulfate, mammalian, and streptococcal hyaluronate. 
A second site of immunoreactivity contains N-acetylgalactosamine, possibly rep- 
resenting autoimmunity to chondroitin or dermatan sulfate PG. 
This work was presented, in part, at the IXth International  Congress  for Nepbrology,June 16, 1984. 
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Materials and  Methods 
Reagents.  DEAE-Sepharose CL-6B and Sepharose CL-4B were obtained from Phar- 
macia Fine Chemicals, Piscataway, NJ. Chondroitinase ABC and heparitinase were pur- 
chased from Miles Laboratories Inc., Elkhart, IN. DEAE-cellulose, pepstatin A, benzam- 
idine-HCl, 6-aminohexanoic acid, guanidine-HCl (grade  1), phenylmethanesulfonyl fluo- 
ride,  N-ethylmaleimide,  N-acetylglucosamine, N-acetylgalactosamine, N-acetylmannosa- 
mine, D-glucuronic acid, and diatomaceous earth (grade  1) were obtained from Sigma 
Chemical Co., St. Louis, MO. Papain (twice crystallized) was from Worthington Biochem- 
ical Corp., Freehold, NJ. Urea (Fisher Scientific Co., Pittsburgh, PA; certified American 
Chemical Society), as an 8 M solution, was passed through a Fisher high-capacity deionizing 
cartidge shortly before use. Standard GAG were provided by Dr. Allen Horwitz, Univer- 
sity of Chicago, including chondroitin-4-sulfate and chondroitin-6-sulfate, hyaluronic acid, 
dermatan sulfate, heparin, and heparan sulfate. Group A streptococcal hyaluronate, and 
group A, A variant, and C carbohydrates were obtained from Dr. Maclyn McCarty, The 
Rockefeller University. 
Human sera were obtained from normal controls and patients with acute and chronic 
PSGN in San Fernando, Trinidad. All patients had appropriate clinical studies, including 
antistreptolysin O  titers and streptococcal cultures, as well as long-term evaluations of 
renal function. Sera from normal controls were also obtained in New York. 
Extraction  of Proteoglycans.  Glomeruli  were  isolated  from  fresh  bovine  or  human 
kidneys by a sieving method (15) and stored frozen. After thawing, the suspension was 
centrifuged at 2,000 g for 10 rain, and the pellet was suspended in 100 vol distilled water 
containing protease inhibitors (0.1  M 6-aminohexanoic acid, 0.01  M EDTA, and 0.005 M 
benzamidine-HCl), stirred for 3 h, and centrifuged at  17,700 g  for 10 min. The pellet 
was resuspended in 4  M guanidine-HCI, 0.05  M sodium acetate, pH 5.8, with protease 
inhibitors, in  10 times the volume of the original pellet; stirred for 48 h, and centrifuged 
as above. A second extraction in the same solvent was performed for 18 h. The combined 
supernatants were dialyzed against three changes of 10 vol deionized 7 M urea, 0.01  M 
EDTA, 0.05  M Tris-HCI, pH 6.5. The extract was then filtered through diatomaceous 
earth, and the cake washed well with 7 M urea buffer. The combined solution was passed 
through a column (80-ml bed vol) of DEAE-Sepharose CL-6B that had been equilibrated 
with 7 M urea buffer. Elution was done stepwise with five bed-volumes each, of increasing 
concentrations of NaCl in 7 M urea-buffer (0.0-1.0  M NaC! in 0.1  M increments). All 
the above steps were carried  out at 4°C.  Each eluate  was dialyzed against water,  and 
lyophilized. The materials that eluted at 0.4 M, 0.5 M, and 0.6 M NaCI were redissolved 
in 0.5  M sodium acetate, pH 5.8, and each was chromatographed at room temperature 
on a column (0.78 ×  110 cm) of Sepharose CL-4B in 0.5 M sodium acetate, pH 5.8. The 
fractions were analyzed, and pooled zones were thoroughly dialyzed against water and 
lyophilized. 
Enzyme-linked  Immunosorbent Assay (ELISA).  ELISA was performed essentially accord- 
ing to the method of Engvall and Perlmann (16),  with Nunc immunoplates (Intermed, 
Denmark).  Various amounts  of antigen  in  50  #!  of 0.1  M  Tris-HCl buffer,  pH  9.8, 
containing 0.3 mM MgCI~, were kept overnight, in wells of the plates, at 4°C. The plates 
were washed once with phosphate-buffered saline (PBS)  containing  0.5%  Brij  (PBSB). 
Nonspecific sites on the plates were blocked by two further incubations with PBSB for 30 
min each. Serum was diluted in PBSB, and 50 #1 were added to the plates for 4 h. The 
plates were washed with 250 #1 of 0.9% NaCI containing 0.5% Brij. An alkaline phospha- 
tase-conjugated goat anti-human IgG (gamma chain-specific) antiserum (lot 88F 9350; 
Sigma Chemical Co.) was added at a dilution of 1:1000 in  50 #1 of PBSB for 4  h. The 
plates were washed in saline-Brij. A developing reagent containing 10 mg of nitrophenyl 
phosphate (Sigma Chemical Co.) in 10 ml of diethanolamine buffer (97 ml diethanolamine, 
1 ml 1 M MgCI2, 1 ml 0.1  M zinc acetate, 0.2 g sodium azide, and 800 ml distilled water, 
pH  9.8)  was added.  The  plates  were  read at  405  nm  in  a  Titertek  Multiskan  (Flow 
Laboratories, McLean, VA) at intervals of up to 4 h. 
Rabbit Antisera to GBM.  Adult  New Zealand White female rabbits were immunized 
with either bovine or human  GBM prepared by the  Meezan (17) procedure.  1 mg of FILLIT ET  AL.  279 
GBM in complete Freund's adjuvant was injected intradermally into two rabbits at 3-wk 
intervals, for a total of three injections. Serum was harvested 1 wk after the final injection. 
Chemical Composition of  Antigenic Preparations.  Uronic acid was measured by a variation 
of the  borate/carbazole  method  (18).  Hexosamines  were  quantitated  on  a  Technicon 
TSM amino acid analyzer after hydrolysis in 4 M He! at 100°C for 8 h (19). Protein was 
measured by a  modified Lowry procedure (20), or by absorbance at 280 nm.  Digestion 
of PG with chondroitinase ABe (0.1  U/mg) was done in 0.1  M  sodium acetate,  0.1  M 
Tris-HCI, containing the following protease inhibitors:  10 mM EDTA,  10 mM N-ethyl- 
maleimide,  1 mM phenylmethanesulfonyl fluoride, and 0.035 mM pepstatin  A, pH 7.3, 
at  37°C,  for  4  h.  Digestion  of PG  with  papain  was  carried  out  in  0.1  M  potassium 
phosphate, 0.01  M EDTA, 0.01  M cysteine, pH 6.8, at 64°C for 18 h with a ratio of PG 
to papain of 100:1. Nitrous acid treatment of PG was carried out as described by Shively 
and Conrad (21).  Heparitinase  digestion  was carried out as described  by Hovingh and 
Linker (22).  All digests were chromatographed on Sepharose  CL-4B in 0.5  M  sodium 
acetate,  pH  5.8.  Intact PG preparations  used as controls were chromatographed under 
identical conditions. 
Results 
Isolation  of PG.  As described in Materials  and Methods, the 4  M guanidine 
extraction  of whole bovine  glomeruli was  fractionated by ion-exchange chro- 
matography on  DEAE-Sepharose  CL-6B.  Fig.  1 shows  the distribution of the 
hexosamine-containing compounds (as measured by aminosugar analysis  [19]). 
The glucosamine content of the unabsorbed and 0.1  M NaCI eluates probably 
represents noncharged glycoproteins and, possibly, low-sulfated GAG. The major 
anionic hexosamine-containing material emerged in 0.4  M, 0.5  M, and 0.6  M 
NaCI eluates. This distribution was probably due to varying degrees of sulfation, 
since  all  three  fractions  gave  similar  profiles  after  gel  chromatography  on 
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FIGURE  I.  Distribution  of hexosamines  in a 4 M guanidine-HCI  extract of glomeruli  after 
DEAE-Sepharose  CL-6B chromatography. F.T., fall through.  Percentages  of glucosamine 
(GlcN) and galactosamine (GalN) in regard to total aminosugar are given. Anionic macromole- 
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Fioullf:  5.  Gel  chromatography  of the  0.4  M  NaCI  DEAE-Sepharose  CL-6B  eluate  on 
Sepharose CL-4B. Peak I contains glucosamine, while peak II contains both glucosamine and 
galactosamine. 
Sepharose CL-4B. Fig. 2 shows a typical profile (0.4 M NaCI eluate). The material 
is resolved into three peaks, all containing protein. Peak 1, emerging in the void 
volume of the column, contains glucosamine and no detectable galactosamine. 
Peak II contains both glucosamine and galactosamine at ~4.5:1.  Uronic acid is 
also present in peak I and peak II. Peak III contains protein or peptides, but no 
hexosamines or uronic acid. As described below, there was no apparent immu- 
nologic difference among the three anionic bovine fractions from DEAE-Seph- 
arose CL-6B. Thus, in the extraction of human glomerular proteoglycan, a single 
fraction was collected encompassing the same range of anionic molecules, and 
referred to as "human-DE 0.6 M." All reported results refer to bovine material 
unless human is specified. 
Characterization  of PG.  The  materials  in  peak  I  and  II,  which  contained 
protein,  uronic acid,  and hexosamine, and were highly anionic, were further 
identified as PG by their susceptibility to specific enzymatic and chemical treat- 
ments. This was tested by chromatography of the material on Sepharose CL-4B 
before and after treatment.  Movement of the material to a  chromatographic 
position with a much higher Kay indicated susceptibility to enzymatic or chemical 
degradation. All fractions were degraded by papain,  indicating their proteina- 
ceous nature.  The  glucosamine-containing component present in  peak  I  was 
susceptible to nitrous acid and heparitinase, as expected of a heparan sulfate. In 
peak II, glucosamine-containing material susceptible to nitrous acid and hepari- 
tinase, and galactosamine-containing material susceptible to chondroitinase ABC, 
were present. These results indicate that peak II contains a mixture of heparan 
sulfate and chondroitin/dermatan sulfate PG, or possibly a hybrid molecule with 
both  kinds  of GAG.  However,  rechromatography of peak  II  material  on  a 
Sepharose CL-4B column, under dissociative conditions, in the presence of 4 M 
guanidine-HCl,  0.5  M  sodium acetate, pH  5.8,  did  not separate  the two  PG 
species. 
Immunologic  Studies  of Glomerular  PG.  We  tested  the  PG  obtained  after 
Sepharose CL-4B chromatography by immunoblotting and ELISA, using human FILLIT  ET  AL.  281 
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FIGURE 3.  (a) ELISA studies of peak II. The antigen is titrated from 10 to 0.1 t~g/ml.  Sera 
from patients with acute PSGN (APSGN) and controls are shown. (b) ELISA studies of peak 
11 (10 pg/ml). Sera from patients with acute PSGN, chronic PSGN (CPSGN), and controls are 
shown. 
sera from controls and patients with PSGN. The Sepharose CL-4B-purified PG 
obtained from the 0.4, 0.5, and 0.6 M NaCI eluates from DEAE-Sepharose CL- 
6B all reacted similarly.  Thus,  the peak  II PG obtained from the 0.4 M  NaCI 
elution of DEAE-Sepharose CI-6B was most extensively studied and is reported 
in detail here. 
In Fig. 3a, using ELISA, the peak II antigen was titrated from  10 to 0.1 pg/ 
ml and tested with sera from a patient with acute PSGN, and a control. We saw 
a clear titration effect as the antigen concentration was changed, indicating that 
ELISA  reactivity  was directed  against  the  antigen  that  was  used  to  coat  the 
plates.  In  a  representative  experiment  (Fig.  3b),  a  clear  titration  curve  of 
reactivity was seen as the serum was diluted and the peak II antigen concentration 
held constant,  indicating that  IgG in the serum being tested accounted for the 
observed antibody binding.  Of 13 acute PSGN sera studied, 6 (46%) contained 
high-titered  antibodies  to peak  II.  Four of  11  (36%) chronic  PSGN  sera  had 
moderate titers of anti-peak II antibody. Only 1 of 11 (9%) control sera contained 
low-titered anti-peak  II antibody. Similar ELISA results with human sera were 
obtained  when  peak  I  antigen  was  used.  Thus,  immunoreactivity  to  isolated 
heparan sulfate PG (peak I) was demonstrated. 282  IMMUNITY  TO  PROTEOGLYCANS 
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FIGURE 4.  ELISA  studies  of peak  II  antigen  (10  #g/ml)  with  an  acute  PSGN  serum, 
performed in the presence of NaCl-at varying concentrations. 
Rabbit antisera made to both bovine and human whole GBM showed high- 
titered reactivity to  the bovine  peak  II  material.  Because the rabbit antisera 
against human GBM reacted with bovine antigen as well, cross-reactivity of the 
bovine peak II material with the equivalent human antigen is apparent. We also 
tested human-DE-0.6M with ELISA. Sera from patients with acute PSGN reacted 
to the human antigen in titers approximating that found with bovine peak II 
antigen. Thus, the bovine and human glomerular PG preparations appear to be 
cross-reactive. 
We performed control experiments to determine whether the PG immuno- 
reactivity was due to  nonspecific ionic binding of cationic IgG,  or to specific 
binding of antibody to the antigenic sites of these anionic molecules. Inhibition 
studies, using the ELISA (Fig. 4), with high concentrations of NaCI (up to 1 M) 
to  inhibit  binding  of the  peak  II  material,  showed essentially no  inhibition. 
Inhibition of acute PSGN sera (1:40 in PBSB) with the peak II material (62.5 
#g/ml) in equal volumes was performed for  1 h  at room temperature and 30 
rain at 4°C, followed by centrifugation at 12,000 g, and use of the supernatant 
for immunologic testing by ELISA. This resulted in specific inhibition of 90% 
of the serum reactivity to the peak II material. 
Inhibition experiments with purified GAG revealed inhibition of acute PSGN 
serum reactivity to peak II only with heparan sulfate, and not with other GAG 
(Fig.  5).  However, further studies with peak  II antigen revealed inhibition of 
acute PSGN serum reactivity with both streptococcal and bovine umbilical cord 
hyaluronate at  ~10-fold higher concentrations than with heparan sulfate (Fig. FILLIT  ET  AL.  283 
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6).  These studies suggest  that  human antibodies against  heparan sulfate  may 
cross-react with mammalian and streptococcal hyaluronate. 
Inhibition experiments with N-acetyigalactosamine alone at concentrations of 
0.5 M showed ~50% inhibition of acute PSGN serum (1:40) reactivity to peak II 
antigen,  while N-acetylglucosamine, a-glucuronic acid,  and  N-acetylmannosa- 
mine showed no inhibition at this concentration. Group C streptococcal carbo- 
hydrate (5 mg/ml), in which the immunodominant carbohydrate is a terminal N- 
acetylgalactosamine disaccharide (23), also inhibited ~50% of acute PSGN serum 
(1:40) reactivity. Group A (immunodominant site containing terminal N-acetyl- 
glucosamine) and A  variant (immunodominant site containing primarily rham- 
nose) (24) streptococcal carbohydrates (5 mg/mi) showed little (9%) inhibition. 
These data indicate the possible presence of a second antigenic site of glomerular 
PG containing N-acetylgalactosamine. 
Since  we  know  (25)  that  acute  PSGN  sera  contain  high  titers  of immune 
complexes, it was possible that the observed serum reactivity to PG might be due 
to the presence of unrelated cationic immune complexes. This possibility was 
examined by polyethylene glycol (PEG) precipitation  of the serum to remove 
immune complexes. We added PEG 8000 (5.4%) in 0.1  M sodium borate buffer 
to acute PSGN sera (1:10) in equal volumes and incubated at 4°C for 1 h. We 
then centrifuged the sera at 12,000 g for 10 min. The supernatant was assayed 
by ELISA using the peak II material as antigen (10 ug/ml). No effect on serum 
reactivity, as judged by serum titer in the ELISA, was noted after removal of the 
immune complexes by this method. Finally, we checked the possibility that the 
serum immunoreactivity might be directed against anionic DNA contaminating 
the peak II antigen. The presence of anti-single/double stranded DNA antibod- 
ies  was  tested by radioimmunoassay in  the  laboratory  of the  late  Dr.  Henry 
Kunkel.  No anti-DNA antibodies were detected in  any of the sera that  were 
reactive to the glomerular PG antigens. 
Discussion 
Biochemical studies show that the materials isolated from bovine and human 
glomeruli contain the components of PG: protein, uronic acid, glucosamine and 
galactosamine, and strong negative charge. Studies using both human and bovine 
antigenic preparations yielded similar results, and rabbit antisera made to human 
GBM cross-reacted with bovine glomerular PG. Peak I, which contains glucosa- 
mine, no detectable galactosamine, and is susceptible to nitrous acid and hepar- 
itinase,  has  the properties  of a  heparan  sulfate  PG.  Enzymatic and  chemical 
susceptibilities demonstrated the presence of heparan sulfate, and either chon- 
droitin sulfate or dermatan sulfate PG in peak II. Since peak II contains both 
GAG, it may be a hybrid PG, or two molecules that cannot be separated even by 
dissociative chromatography in  4  M  guanidine-HCl.  Immunologic studies  re- 
vealed the presence of antibodies  in  PSGN  sera  to  peak  I  and  peak  II  PG. 
Antibodies to peak I indicate specific immunoreactivity to glomerular heparan 
sulfate PG.  The antigenic specificity of these sera was further investigated in 
ELISA inhibition experiments, and two carbohydrate immunodeterminants were 
identified: heparan sulfate and a second antigenic site containing N-acetylgalac- FILLIT  ET  AL.  285 
tosamine. PSGN sera may also contain antibodies to PG protein core determi- 
nants; this will require further investigation. 
Charge interactions could play an important role in antibody binding to the 
highly charged  PG  molecules.  Faaber  et al.  (8)  suggested that  the  anti-DNA 
antibodies in SLE sera, which cross-react with GAG, bind primarily on a charge 
basis, to polyanionic molecules in general. Our studies indicated that the heparan 
sulfate-antibody reaction was not due to nonspecific charge interactions.  The 
GN  sera  we studied did not  contain antibodies  to single- or double-stranded 
DNA by radioimmunoassay, which would have been expected if broadly reactive 
antibodies with strongly cationic combining sites were present. Charge binding 
was  further  ruled  out  by  the  observation  that  1  M  NaCI  had  no  effect  on 
immunoreactivity in the ELISA. In addition, cationic immune complexes were 
not found to account for the observed reactivity. Finally, the finding of similar 
immunoreactivity to the 0.4, 0.5, and 0.6 M  NaCI eluates of DEAE-Sepharose 
CL-6B that were further purified by Sepharose CL-4B also indicated that the 
heterogeneous charge  nature  of the  PG  had  no detectable  influence on  the 
overall antigenicity of the molecule. Thus, our observations indicate that immune 
reactivity to PG in PSGN sera may be directed, in part, toward highly specific 
carbohydrate determinants, and is not due to nonspecific charge interactions. 
We studied the nature of the specific carbohydrate antigenic sites responsible 
for immunoreactivity to giomerular PG in ELISA inhibition experiments. The 
specific antigenic site of polysaccharides may contain either a monosaccharide or 
multiple units of repeating disaccharides.  Heparan  sulfate is a  repeating disac- 
charide  containing glucuronic acid  and  N-acetylglucosamine.  Although  these 
monosaccharides are  individually antigenic (3,  24),  it appears,  from our data, 
that the antigenic site of heparan sulfate defined by PSGN sera contains multiple 
repeating  disaccharide  units.  The  monosaccharides,  N-acetylglucosamine and 
glucuronic acid, did not inhibit the binding of acute PSGN sera to glomerular 
PG,  but  the  polysaccharide  heparan  sulfate  was  able  to inhibit  the  observed 
immunoreactivity. These results regarding the nature of the heparan sulfate site 
are consistent with the observation of Kahat (26) that the optimum binding site 
of polysaccharide antigens may require several repeating disaccharide units for 
the best fit into the antibody-combining site. 
Immune reactivity to a  N-acetylgalactosamine site of peak II  was shown by 
inhibition experiments using N-acetylgalactosamine monosaccharide and group 
C  carbohydrate.  Inhibitions with GAG containing N-acetylgalactosamine (such 
as  chondroitin  or  dermatan  sulfate)  were  unremarkable.  Although  the  exact 
nature of the N-acetylgalactosamine site in the peak II PG remains unknown, it 
is possible that this site represent  s chondroitin/dermatan sulfate, which we have 
not  been  able  to  demonstrate  by  our  inhibition  experiments.  Chondroitin/ 
dermatan sulfate is present in our peak II material and is probably derived from 
the glomerular mesangium (7), which was likely included in our 4 M guanidine 
extract of whole glomeruli. Immune reactivity to chondroitin sulfate appears to 
be  directed  primarily  against  antigenic  moieties  that  are  exposed  only  after 
enzymatic treatment that reveals hidden antigenic sites (6, 27). Thus, our inability 
to  detect  chondroitin  sulfate  antibodies  by  inhibition  with  intact  GAG  may 
indicate that a  hidden N-acetylgalactosamine determinant contains the immu- 286  IMMUNITY  TO  PROTEOGLYCANS 
nodominant site of antibodies in PSGN sera. Inhibition experiments with chon- 
droitinase-digested  chondroitin sulfate  fragments  (6,  27)  will  be  necessary  to 
determine if this hypothesis is correct. 
The  PSGN  sera  we  studied  contained  antibodies  to  heparan  sulfate  that 
appeared to be cross-reactive with hyaluronate. This cross-reaction may have a 
molecular basis, since both hyaluronate and heparan sulfate have similar repeat- 
ing disaccharide units of N-acetyiglucosamine and glucuronic acid. The differ- 
ences in the linkages and sulfation of these GAG could account for the differences 
in ELISA inhibitory capability of these molecules on an equivalent weight basis. 
We noted inhibition with both mammalian and streptococcal hyaluronate, which 
are thought to be identical (M. McCarty, personal communication). The inhibi- 
tion of immunoreactivity of PSGN  sera  with hyaluronate  in our experiments 
suggests  that  antibodies  to  hyaluronate  are  present.  Finally,  the  finding  of 
antibodies to a  PG site containing N-acetylgalactosamine that are inhibited by 
group C streptococcal carbohydrate may indicate the presence of another cross- 
reaction between  PG and streptococci.  It is possible that antibodies to the N- 
acetylgalactosamine site  were  induced by  group  C  streptococcal  infections in 
these patients. 
In studies of carbohydrate immunity to artificial antigens, Avery's group (28) 
demonstrated the marked degree of specificity exhibited by antisera to carbo- 
hydrate antigens. Immune sera were capable of distinguishing synthetic protein- 
conjugated alpha or beta glucoside antigens (28), and synthetic protein-conju- 
gated glucuronic or galacturonic acid antigens (4). These findings led Avery (28) 
to the conclusion that the immunological specificity of carbohydrates is deter- 
mined by the subleties of their chemical structure. 
However,  Goebel  and  Hotchkiss (4)  eventually indicated that antibodies to 
anionic carbohydrates may be of two types, carbohydrate-specific antibodies and 
nonspecific antibodies binding anionic groups. In antipneumococcus horse sera, 
antibodies reactive with pneumococcal polysaccharide (containing uronic acid) 
cross-reacted with synthetic uronic acid-protein antigens.  One group of these 
antibodies was specific for carbohydrate  moieties, and were inhibited only by 
glucuronic acid and not by other anionic antigens, including galacturonic acid. 
A second group of antipneumococcal polysaccharide antibodies were precipitated 
nonspecifically by a  number of anionic antigens, including glucuronic and gal- 
acturonic acids, as well as unrelated anionic molecules such as p-aminobenzoic, 
carboxylic and suifonic acids. The broad reactivity to anionic groups could be 
absorbed by pneumococcal polysaccharide, and was not found in normal horse 
serum,  indicating  that  these  broadly  reactive  antibodies  were  of an  immune 
nature,  and  presumably  contained  cationic  groups  in  their  combining  sites. 
Fischetti (29) and others (30) later demonstrated that anionic antigens may elicit 
antibodies with cationic combining sites. 
In light of these earlier observations, and based on our current findings and 
those of Faaber  et  al.  (8),  we conclude that  the  human immune response to 
anionic GAG apparently produces both nonspecific antibodies broadly reactive 
with  anionic  molecules,  and  antibodies  that  recognize  specific  carbohydrate 
immunodeterminants.  The  mechanism  accounting  for  the  induction  of  PG 
autoimmunity in disease is not known. After inflammatory injury, the exposure FILLIT ET AL.  287 
of hidden or altered PG antigens to the immune system could result in the onset 
of PG autoimmunity in a genetically predisposed host. Autoimmunity to heparan 
sulfate in  patients  with  PSGN  may be induced by cross-reactive streptococcal 
capsular hyaluronate during infections. The resultant autoimmunity to heparan 
sulfate PG could cause the progression  of acute PSGN  to chronicity in  some 
patients many years after the inducing streptococcal antigen has disappeared. 
The role of PG autoimmunity in pathogenesis requires further investigation. In 
autoimmune connective tissue diseases such as SLE, the broad range of organs 
involved  could  be  related  to  the  presence of nonspecific antibodies  broadly 
reactive with anionic molecules, including PG, while in organ,specific diseases, 
such as GN, antibodies directed towards specific PG immunodeterminants in- 
volve  only  specific  target  organs.  Since  heparan  sulfate  PG  contributes  the 
majority of anionic charges to the filtration barrier of the basement membrane, 
and blocking these sites leads to proteinuria (31), autoimmunity to glomerular 
heparan sulfate PG could cause proteinuria in patients with GN. 
Summary 
Antibodies, found in human sera from patients with poststreptococcal glomer- 
ulonephritis, against proteoglycans (PG) derived from bovine and human glo- 
meruli were investigated. PG were isolated by 4 M guanidine-HC! extraction of 
whole glomeruli, followed by DEAE-Sepharose CL-6B ion exchange chromatog- 
raphy.  The  anionic  fractions  were  further  purified  by  chromatography  on 
Sepharose CL-4B.  Biochemical analysis of the two resulting peaks revealed the 
presence of high molecular weight anionic material containing protein, uronic 
acid,  glucosamine, and  galactosamine.  Enzymatic and chemical susceptibilities 
indicated the presence of heparan sulfate PG and a  galactosamine-containing 
PG. 
Immunologic studies revealed the presence of anti-PG antibodies to both PG 
peaks of the Sepharose CL-4B column in  glomerulonephritis sera.  Inhibition 
studies using an ELISA demonstrated that heparan sulfate was a major antigenic 
determinant. Cross-reactivity with both mammalian and streptococcal hyaluron- 
ate was noted. Inhibition studies also indicated the presence of a second antigenic 
site containing N-acetylgalactosamine, possibly representing chondroitin or der- 
matan sulfate PG. 
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